Beginning by screening 110 NR ligands against a panel of 90 patient derived NSCLC lines, we found a subset that are dramatically growth inhibited both in vitro and in vivo by multiple GR agonists. This evidence concerns the gene NR3C1 and non-small cell lung carcinoma.